Advanced search
Publication Cover
Aging Health Volume 2, 2006 - Issue 6
Journal homepage
48
Views
0
CrossRef citations to date
0
Altmetric
Review

Homocysteine as an Emerging Risk Factor for Cardiovascular Disease in the Elderly

Betti Giusti1 Department of Medical and Surgical Critical Care and Center of Research, Transfer and High Education, “DENOTHE”, University of Florence, viale Morgagni 85, 50134Florence, Italy Tel.: +39 055 794 9420; Fax: +39 055 794 9418;2 E-mail: [email protected]
,
Anna Maria Gori1 Department of Medical and Surgical Critical Care and Center of Research, Transfer and High Education, “DENOTHE”, University of Florence, viale Morgagni 85, 50134Florence, Italy Tel.: +39 055 794 9420; Fax: +39 055 794 9418;3 E-mail: [email protected]
,
Rossella Marcucci1 Department of Medical and Surgical Critical Care and Center of Research, Transfer and High Education, “DENOTHE”, University of Florence, viale Morgagni 85, 50134Florence, Italy Tel.: +39 055 794 9420; Fax: +39 055 794 9418;4 E-mail: [email protected]
,
Claudia Saracini1 Department of Medical and Surgical Critical Care and Center of Research, Transfer and High Education, “DENOTHE”, University of Florence, viale Morgagni 85, 50134Florence, Italy Tel.: +39 055 794 9420; Fax: +39 055 794 9418
,
Paola Bolli1 Department of Medical and Surgical Critical Care and Center of Research, Transfer and High Education, “DENOTHE”, University of Florence, viale Morgagni 85, 50134Florence, Italy Tel.: +39 055 794 9420; Fax: +39 055 794 9418;5 Centro S Maria agli Ulivi Fondazione Don Carlo Gnocchi Onlus IRCCS, Impruneta, Florence, Italy
&
Rosanna Abbate1 Department of Medical and Surgical Critical Care and Center of Research, Transfer and High Education, “DENOTHE”, University of Florence, viale Morgagni 85, 50134Florence, Italy Tel.: +39 055 794 9420; Fax: +39 055 794 9418;6 E-mail: [email protected]
Pages 983-997 | Published online: 14 Dec 2006

Bibliography

  • Butler RN : Population aging and health.BMJ315, 1082–1084(1997).
  • Lakatta EG , LevyD: Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part 1: aging arteries: a “set-up” for vascular disease.Circulation107, 139–146(2003).
  • Celermajer DS , SorensenKE, Speigelhalter DJ et al.: Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J. Am. Coll. Cardiol.24, 471–476(1994).
  • McCully KS : Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis.Am. J. Pathol.111–128(1969).
  • McCully KS : Homocysteine and vascular disease.Nat. Med.2, 236–239(1996).
  • Bautista L , ArenasI, PenuelaA et al.: Total plasma homocysteine level and risk of cardiovascular disease: a meta-analysis of prospective cohort studies. J. Clin. Epidemiol.55, 882–887(2002).
  • Homocysteine Studies Collaboration: Homocysteine and risk of ischemic heart disease and stroke: meta-analysis. JAMA288, 2015–2022(2002).
  • Klerk M , VerhoefP, ClarkeR et al.: MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. J. Am. Med. Ass.288, 2023–2031(2002).
  • Wald DS , LawM, MorrisJK: Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis.BMJ325, 1202–1208(2002).
  • Hankey GJ , EikelboomJW: Homocysteine and stroke.Lancet365, 194–196(2005).
  • Kaul S , ZadehAA, ShahPKS: Homocysteine hypothesis for atherotrombotic cardiovascular disease: not validated.J. Am. Coll. Cardiol.48, 914–923(2006).
  • Hankey GJ , EikelboomJW: Homocysteine and vascular disease.Lancet354, 407–413(1999).
  • Selhub J : Homocysteine metabolism.Ann. Rev. Nutr.19, 217–246(1999).
  • Rozen R : Genetic modulation of homocysteinemia.Semin. Thromb. Hemost.26, 255–261(2000).
  • Ueland PM , HustadS, SchneedeJ et al.: Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol. Sci.22, 195–201(2001).
  • Bots ML , LaunerLJ, LindemansJ et al.: Homocysteine and short-term risk of myocardial infarction and stroke in elderly: the Rotterdam Study. Arch. Intern. Med.159, 38–44(1999).
  • Nygard O , VollsetSE, RefsumH et al.: Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA274, 1526–1533(1995).
  • Selhub J , JacquesPF, RosenbergIH et al.: Serum total homocysteine concentrations in the Third National Health and Nutrition Examination Survey (1991–1994): population reference ranges and contribution of vitamin status to high serum concentrations. Ann. Intern. Med.131, 331–339(1999).
  • Bostom AG , SilbershatzH, RosenbergIH et al.: Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch. Intern. Med.159, 1077–1080(1999)
  • Giri S , ThompsonP, TaxelP et al.: Oral estrogen improves serum lipids, homocysteine and fibrinolysis in eldery men. Atherosclerosis137, 359–366(1997).
  • Mjatovic V , NetelenbosC, MoorenMJ et al.: Randomized, double-blind, placebo-controlled study on the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women. Fertil. Steril.70, 1085–1089(1998).
  • Van baal M , SmoldersR, Van der Mooren M et al.: Hormone replacement therapy and plasma homocysteine levels. Obstet. Gynecol.94, 485–491(1999).
  • Mjatovic V , KenemansP, JakobsC et al.: A randomized controlled study of the effects of 17β-estradiol-dydrogesterone on plasma homocysteine in postmenopausal women. Obstet. Gynecol.91, 432–436(1998).
  • O‘Connor D , GreenT, PiccianoM: Maternal folate status and lactation.J. Mammary Gland Biol. Neoplasia2, 279–289(1997).
  • Steegers-Theunissen R , WathenN, EskesT et al.: Maternal and fetal levels of methionine and homocysteine in early human pregnancy. Br J Obstet. Gynecol.104, 20–24(1997).
  • Moustapha A , RobinsonK: High plasma homocysteine: a risk factor for vascular disease in the elderly.Coron. Artery Dis.9, 725–730(1998).
  • Kannel WB : Cardiovascular risk factors in the elderly.Coron. Artery Dis.8, 565–575(1997).
  • Bates CJ , MansoorMA, van der Pools J et al.: Plasma total homocysteine in a representative sample of 972 British men and women aged 65 and over. Eur. J. Clin. Nutr.51, 691–697(1997).
  • Selhub J , JacquesPF, WilsonPWF et al.: Vitamin status and intake as primary determinants of homocysteine in the elderly. JAMA270, 2693–2698(1993).
  • Jacques PF , RosenbergIH, RogersG et al.: Serum total homocysteine concentrations in adolescent and adult Americans: results from the third National Health and Nutrition Examination Survey. Am. J. Clin. Nutr.69, 482–489(1999).
  • Nurk E , TellGS, VollsetSE et al.: Changes in lifestyle and plasma total Homocysteine: the Hordaland Homocysteine Study. Am. J. Clin. Nutr.79, 812–819(2004).
  • Gori AM , CorsiAM, FediS et al.: A proinflammatory state is associated with hyperhomocysteinemia in the elderly. Am. J. Clin. Nutr.82(2), 335–341(2005).
  • Tucker KL , SelhubJ, WilsonPW et al.: Dietary intake pattern relates to plasma folate and homocysteine concentrations in the Framingham Heart Study. J. Nutr.126(12), 3025–3031(1996).
  • Morris MS , JacquesPF, RosenbergIH et al.: Serum total homocysteine concentration is related to self-reported heart attack or stroke history among men and women in the NHANES III. J. Nutr.130(12), 3073–3076(2000).
  • Rader JI : Folic acid fortification, folate status and plasma homocysteine.J. Nutr.132(8 Suppl.), 2466S–2470S (2002).
  • Nygard O , RefsumH, UelandPM et al.: Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland Homocysteine Study. Am. J. Clin. Nutr.67(2), 263–270(1998).
  • Guttormsen AB , UelandPM, SvarstadE et al.: Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int.52(2), 495–502(1997).
  • Refsum H , UelandPM, NygardO et al.: Homocysteine and cardiovascular disease. Annu. Rev. Med.49, 31–62(1998).
  • Gale CR , AshurstH, PhillipsNJ et al.: Renal function, plasma homocysteine and carotid atherosclerosis in elderly people. Atherosclerosis154(1), 141–146(2001).
  • Krasinski SD , RussellRM, SamloffIM et al.: Fundic atrophic gastritis in an elderly population. Effect on hemoglobin and several serum nutritional indicators. J. Am. Geriatr. Soc.34(11), 800–806(1986).
  • Rozen R : Genetic predisposition to hyperhomocysteinemia: deficiency of methylenetetrahydrofolate reductase (MTHFR).Thromb. Haemost.78, 523–526(1997).
  • Weisberg I , TranP, ChristensenB et al.: A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol. Genet. Metab.64, 169–172(1998).
  • Sharp L , LittleJ: Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review.Am. J. Epidemiol.159, 423–443(2004).
  • Girelli D , FrisoS, TrabettiE et al.: Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic–environmental interaction. Blood91, 4158–4163(1998).
  • Friso S , ChoiSW, GirelliD et al.: A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc. Natl Acad. Sci. USA99(8), 5606–5611(2002).
  • De Bree A , VerschurenWM, Bjorke-MonsenAL et al.: Effect of the methylenetetrahydrofolate reductase 677C→T mutation on the relations among folate intake and plasma folate and homocysteine concentrations in a general population sample. Am. J. Clin. Nutr.77, 687–693(2003).
  • Gori AM , SofiF, CorsiAM et al.: Predictors of vitamin B6 and folate concentrations in elderly: the InChianti Study. Clin. Chem.52(7), 1318–1324(2006).
  • Molloy AM , DalyS, MillsJL et al.: Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations. Lancet31, 349(9065), 1591–1593(1997).
  • Brattstrom L , ZhangY, HurtigM et al.: A common methylenetetrahydrofolate reductase gene mutation and longevity. Atherosclerosis141(2), 315–319(1998).
  • Fatini C , SofiF, GoriAM et al.: Endothelial nitric oxide synthase -786T>C, but not 894G>T and 4a4b, polymorphism influences plasma homocysteine concentrations in persons with normal vitamin status. Clin. Chem.51, 1159–1164(2005).
  • Bates CJ , MansoorMA, van der Pols J et al.: Plasma total homocysteine in a representative sample of 972 British men and women aged 65 and over. Eur. J. Clin. Nutr.51, 691–697(1997).
  • Evans RW , ShatenBJ, HempelJD et al.: Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler. Thromb. Vasc. Biol.17, 1947–1953(1997).
  • De Jong SC , StehouwerCD, van den Berg M et al.: Endothelial marker proteins in hyperhomocysteinemia. Thromb. Haemost.78, 1332–1337(1997).
  • Rohde LE , HennekensCH, RidkerPM: Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men.Am. J. Cardiol.84, 1018–1022(1999).
  • Mangoni AA , JacksonSH: Homocysteine and cardiovascular disease: current evidence and future prospects.Am. J. Med.112, 556–565(2002).
  • Faraci FM : Hyperhomocysteinemia: a million ways to lose control.Arterioscler. Thromb. Vasc. Biol.23, 371–373(2003).
  • Upchurch GR Jr, Welch GN, Fabian AJ et al.: Stimulation of endothelial nitric oxide production by homocyst(e)ine. Atherosclerosis25, 132(2), 177–185(1997).
  • Friso S , JacquesPF, WilsonPW et al.: Low circulating vitamin B(6) is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine concentrations. Circulation103, 2788–2791(2001).
  • Rohde LE , HennekensCH, RidkerPM: Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men.Am. J. Cardiol.84, 1018–1022(1999).
  • Folsom AR , DesvarieuxM, NietoFJ et al.: B vitamin status and inflammatory markers. Atherosclerosis169, 169–174(2003).
  • Ravaglia G , FortiP, MaioliF et al.: Plasma homocysteine and inflammation in elderly patients with cardiovascular disease and dementia. Exp. Gerontol.39, 443–450(2004).
  • Welch GN , LoscalzoJ: Homocysteine and atherothrombosis.N. Engl. J. Med.338, 1042–1050(1998).
  • Egerton W , SilberbergJ, CrooksR et al.: Serial measures of plasma homocyst(e)ine after acute myocardial infarction. Am. J. Cardiol.77, 759–761(1996).
  • Lindgren A , BrattstromL, NorrvingB et al.: Plasma homocysteine in the acute and convalescent phases after stroke. Stroke26, 795–800(1995).
  • Dudman NP : An alternative view of homocysteine.Lancet354, 2072–2074(1999).
  • Roubenoff R , HarrisTB, AbadLW et al.: Monocyte cytokine production in an elderly population: effect of age and inflammation. J. Gerontol. A. Biol. Sci. Med. Sci.53, M20–M26 (1998).
  • Ferrucci L , CorsiAM, LauretaniF et al.: The origins of age-related pro-inflammatory state. Blood105, 2294–2299(2005).
  • Jakubowski H : Molecular basis of homocysteine toxicity in humans.Cell Mol. Life Sci.61, 470–487(2004).
  • Hernanz A , Fernandez-VivancosE, Montiel C et al.: Changes in the intracellular homocysteine and glutathione content associated with aging. Life Sci.67, 1317–1324(2000).
  • Dong C , YoonW, Goldschmidt-Clermont PJ:DNA methylation and atherosclerosis. J. Nutr.132(8 Suppl.), 2406S–2409S (2002).
  • Wainfan E , PoirierLA: Methyl groups in carcinogenesis: effects on DNA methylation and gene expression.Cancer Res.52, 2071–2077(1992).
  • Pogribny IP , PoirierLA, JamesSJ: Differential sensitivity to loss of cytosine methyl groups within the hepatic p53 gene of folate/methyl deficient rats.Carcinogenesis16, 2863–2867(1995).
  • Roubenoff R , HarrisTB, AbadLW et al.: Monocyte cytokine production in an elderly population: effect of age and inflammation. J. Gerontol. A. Biol. Sci. Med. Sci.53, M20–M26 (1998).
  • Chang CL , MarraGC, ChauhanDP et al.: Oxidative stress inactivates the human DNA mismatch repair system. Am. J. Physiol. Cell Physiol.283, C148–C154 (2002).
  • Obeid R , SchorrH, EckertR et al.: Vitamin B12 status in the elderly as judged by available biochemical markers. Clin. Chem.50, 238–241(2004).
  • Herrmann W , ObeidR, SchorrH et al.: Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism and the B-vitamins: a facet of nature–nurture interplay. Clin. Chem. Lab. Med.41, 547–553(2003).
  • Stampfer MJ , MalinowMR, WillettWC et al.: A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA268, 877–881(1992).
  • Pancharuniti N , LewisCA, SauberlichHE et al.: Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am. J. Clin. Nutr.59, 940–948(1994).
  • Nygard O , NordrehaugJE, RefsumH et al.: Plasma homocysteine levels and mortality in patients with coronary artery disease. N. Engl. J. Med.337, 230–236(1997).
  • Anderson JL , MuhlesteinJB, HorneBD et al.: Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation102, 1227–1232(2000).
  • Stubbs PJ , Al-ObaidiMK, ConroyRM et al.: Effect of plasma homocysteine concentration on early and late events in patients with acute coronary syndromes. Circulation102, 605–610(2000).
  • Aronow WS , AhnC: Association between plasma homocysteine and coronary artery disease in older persons.Am. J. Cardiol.80, 1216–1218(1997).
  • Lindeman RD , RomeroLJ, YauCL et al.: Serum homocysteine concentrations and their relation to serum folate and vitamin B12 concentrations and coronary artery disease prevalence in an urban, bi-ethnic community. Ethn. Dis.13, 178–185(2003).
  • Stehouwer CD , WeijenbergMP, van den BergM et al.: Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year follow-up. Arterioscler. Thromb. Vasc. Biol.18, 1895–1901(1998).
  • Ridker PM , MansonJE, BuringJE et al.: Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA281, 1817–1821(1999).
  • Nurk E , TellGS, VollsetSE et al.: Plasma total homocysteine and hospitalizations for cardiovascular disease: the Hordaland Homocysteine Study. Arch. Intern. Med.162, 1374–1381(2002).
  • Bostom AG , SilbershatzH, RosenbergIH et al.: Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch. Intern. Med.159, 1077–1080(1999).
  • Kark JD , SelhubJ, AdlerB et al.: Nonfasting plasma total homocysteine level and mortality in middle-aged and elderly men and women in Jerusalem. Ann. Intern. Med.131, 321–330(1999).
  • Vollset SE , RefsumH, TverdalA et al.: Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland Homocysteine Study. Am. J. Clin. Nutr.74, 130–136(2001).
  • Kawamoto R , KajiwaraT, OkaY et al.: An association between plasma homocysteine concentrations and ischemic stroke in elderly Japanese. J. Atheroscler. Thromb.9, 121–125(2002).
  • Matsui T , AraiH, YuzurihaT et al.: Elevated plasma homocysteine levels and risk of silent brain infarction in elderly people. Stroke32, 1116–1119(2001).
  • Bertsch T , MielkeO, HolyS et al.: Homocysteine in cerebrovascular disease: an independent risk factor for subcortical vascular encephalopathy. Clin. Chem. Lab. Med.39, 721–724(2001).
  • Vermeer SE , van Dijk EJ, Koudstaal PJ et al.: Homocysteine, silent brain infarcts, and white matter lesions: the Rotterdam Scan Study. Ann. Neurol.51, 285–289(2002).
  • Bots ML , LaunerLJ, LindemansJ et al.: Homocysteine, atherosclerosis and prevalent cardiovascular disease in the elderly: the Rotterdam Study. J. Intern. Med.242, 339–347(1997).
  • Kario K , DuellPB, MatsuoT et al.: High plasma homocyst(e)ine levels in elderly Japanese patients are associated with increased cardiovascular disease risk independently from markers of coagulation activation and endothelial cell damage. Atherosclerosis157, 441–449(2001).
  • Casas JP , BautistaLE, SmeethL et al.: Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet365, 224–232(2005).
  • Vermeer SE , Den Heijer T, Koudstaal PJ et al.: Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke34, 392–396(2003).
  • Marcucci R , SofiF, FediS et al.: Thrombophilic risk factors in patients with severe carotid atherosclerosis. J. Thromb. Haemost.3(3), 502–507(2005).
  • Marcucci R , ZanazziM, BertoniE et al.: Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients. Transplantation75(9), 1551–1555(2003).
  • Go AS , HylekEM, PhillipsKA et al.: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA285, 2370–2375(2001).
  • Benjamin EJ , WolfPA, D‘AgostinoRB et al.: Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation98, 946–952(1998).
  • Marcucci R , BettiI, CecchiE et al.: Hyperhomocysteinemia and vitamin B6 deficiency: new risk markers for nonvalvular atrial fibrillation? Am. Heart J.148, 456–461(2004).
  • Poli D , AntonucciE, CecchiE et al.: Culprit factors for the failure of well-conducted warfarin therapy to prevent ischemic events in patients with atrial fibrillation: the role of homocysteine. Stroke36(10), 2159–2163(2005).
  • Nattel S , Shiroshita-TakeshitaA, CardinS et al.: Mechanisms of atrial remodelling and clinical relevance. Curr. Opin. Cardiol.20, 21–25(2005).
  • Hunt MJ , TyagiSC: Peroxisome proliferators compete and ameliorate Hcy-mediated endocardial endothelial cell activation.Am. J. Physiol. Cell. Physiol.283, C1073–C1079 (2002).
  • Bescond A , AugierT, ChareyreC et al.: Influence of homocysteine on matrix metalloproteinase-2: activation and activity. Biochem. Biophys. Res. Commun.263, 498–503(1999).
  • Sood HS , HuntMJ, TyagiSC: Peroxisome proliferator ameliorates endothelial dysfunction in a murine model of hyperhomocysteinemia.Am. J. Physiol. Lung Cell. Mol. Physiol.284, L333–L341 (2003).
  • Krumdieck CL , PrinceCW: Mechanisms of homocysteine toxicity on connective tissues: implications for the morbidity of aging.J. Nutr.130(2S Suppl.), 365S–368S (2000).
  • Giusti B , PorcianiMC, BrunelliT et al.: Phenotypic variability of cardiovascular manifestations in Marfan Syndrome. Possible role of hyperhomocysteinemia and C677T MTHFR gene polymorphism. Eur. Heart J.24, 2038–2045(2003).
  • Giusti B , MarcucciR, LapiniI et al.: Role of hyperhomocysteinemia in aortic disease. Cell. Mol. Biol. (Noisy-le-grand).50, 945–952(2004).
  • Herrmann M , Taban-ShomalO, HubnerU et al.: A review of homocysteine and heart failure. Eur. J. Heart Failure (2006).
  • Naruszewicz M , JankowskaEA, Zymlinski R et al.: Hyperhomocysteinemia in patients with symptomatic chronic heart failure: Prevalence and prognostic importance-pilot study. Atherosclerosis DOI 10.1016/j.atherosclerosis.2006.08.014 (2006) (Epub ahead of print).
  • Gibelin P , SerreS, CanditoM et al.: Prognostic value of homocysteinemia in patients with congestive heart failure. Clin. Chem. Lab. Med.44, 813–816(2006).
  • Selhub J : The many facets of hyperhomocysteinemia: studies from the Framingham cohorts.J. Nutr.136(6 Suppl.), 1726S–1730S (2006).
  • Andersson SE , EdvinssonML, EdvinssonL: Cutaneous vascular reactivity is reduced in aging and in heart failure: association with inflammation.Clin. Sci.105, 699–707(2003).
  • Splaver A , LamasGA, HennekensCH: Homocysteine and cardiovascular disease: Biological mechanisms, observational epidemiology, and the need for randomized trials.Am. Heart J.148, 34–40(2004).
  • Hofmann MA , LallaE, LuY et al.: Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J. Clin. Invest.107(6), 675–683(2001).
  • Andersson SE , EdvinssonML, EdvinssonL: Reduction of homocysteine in elderly with heart failure improved vascular function and blood pressure control but did not affect inflammatory activity.Basic Clin. Pharmacol. Toxicol.97, 306–310(2005).
  • Brunelli T , PriscoD, FediS et al.: High prevalence of mild hyperhomocysteinemia in patients with abdominal aortic aneurysm. J. Vasc. Surg.32, 531–536(2000).
  • Sofi F , MarcucciR, GiustiB et al.: High levels of homocysteine, lipoprotein (a) and plasminogen activator inhibitor-1 are present in patients with abdominal aortic aneurysm. Thromb. Haemost.94, 1094–1098(2005).
  • Pezzini A , Del Zotto E, Padovani A: Hyperhomocysteinemia: a potential risk factor for cervical artery dissection following chiropractic manipulation of the cervical spine. J. Neurol.249, 1401–1403(2002).
  • Bescon A , AugierT, ChareyreC et al.: Homocysteine-induced elastolysis in arterial media: activation of MMP2. Neth. J. Med.58, S56–S57 (1998).
  • Jourdheuil-Rahmani D , RollandPH, Rosset E et al.: Homocysteine induces synthesis of a serine elastase in arterial smooth muscle cells from multi-organ donors. Cardiovasc. Res.34, 597–602(1997).
  • Segura AM , LunaRE, HoribaK et al.: Immunohistochemistry of matrix metalloproteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of patients with Marfan’s syndrome. Circulation98, II331–II337 (1998).
  • Keeling WB , ArmstrongPA, StonePA et al.: An overview of matrix metalloproteinases in the pathogenesis and treatment of abdominal aortic aneurysms. Vasc. Endovascular Surg.39(6), 457–464(2005).
  • Shimizu K , MitchellRN, LibbyP: Inflammation and cellular immune responses in abdominal aortic aneurysms.Arterioscler. Thromb. Vasc. Biol.26(5), 987–994(2006).
  • B-vitamin treatment trialists’ collaboration Oxford, United Kingdom: Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am. Heart J.151, 282–287(2006).
  • Vermeulen EG , StehouwerCD, TwiskJW et al.: Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet355(9203), 517–522(2000).
  • Schnyder G , RoffiM, PinRet al.: Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N. Engl. J. Med.345(22), 1593–1600(2001).
  • Schnyder G , RoffiM, FlammerY, PinR, HessOM: Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial.JAMA288(8), 973–979(2002).
  • Lange H , SuryapranataH, De Luca G et al.: Folate therapy and in-stent restenosis after coronary stenting. N. Engl. J. Med.350(26), 2673–2681(2004).
  • Toole JF , ManilowMR, ChamblessLEet al.: Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA291(5), 565–575(2004).
  • Bonaa KH , NjolstadI, UelandPM et al.; NORVIT Trial Investigators: Homocysteine lowering and cardiovascular events after acute myocardial infarction. N. Engl. J. Med.354(15), 1578–1588(2006).
  • Lonn E , YusufS, ArnoldMJet al.; Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators: Homocysteine lowering with folic acid and B vitamins in vascular disease. N. Engl. J. Med.354(15), 1567–1577(2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.